154 research outputs found

    Computational Modeling of the Experimental Response of Microscale Bistable Tensegrity Structures

    Get PDF
    We report about the analysis, design, and experimental testing of modular structures composed of bistable units derived from the classic triangular tensegrity prism. Tensegrity structures are pinconnected frameworks, composed by bars and cables, possessing internal mechanisms and self-stress states, and featuring a variety of structural responses depending on their prestress, edge connectivity, and geometry. When a tensegrity system has only one internal mechanism and one self-stress state, as in the triangular prism case, it is possible to associate to it a corresponding bistable unit, by replacing all cables with bars and changing their edge-lengths slightly. After presenting experimental results of compression tests carried out on microscale specimens fabricated through multiphoton lithography, we compare them with the numerical predictions obtained by our computational model

    Mission-based hull-form and propeller optimization of a transom stern destroyer for best performance in the sea environment

    Get PDF
    An overview is presented of the activities conducted within the NATO STO Task Group AVT-204 to “Assess the Ability to Optimize Hull Forms of Sea Vehicles for the Best Per- formance in a Sea Environment.” The objective is the development of a greater understanding of the potential and limitations of the hydrodynamic optimization tools. These include low- and high-fidelity solvers, automatic shape modification methods, and multi-objective optimiza- tion algorithms, and are limited here to a deterministic application. The approach includes simulation-based design optimization methods from different research teams. Analysis tools include potential flow and Reynolds-averaged Navier-Stokes equation solvers. Design modifica- tion tools include global modification functions, control point based methods, and parametric modelling by hull sections and basic curves. Optimization algorithms include particle swarm optimization, sequential quadratic programming, genetic and evolutionary algorithms. The ap- plication is the hull-form and propeller optimization of the DTMB 5415 model for significant conditions, based on actual missions at sea

    Pitfalls in the Diagnosis of Anaplastic Large Cell Lymphoma with a Small Cell Pattern

    Get PDF
    Anaplastic large cell lymphoma with a small cell pattern is a rare T-cell lymphoma. This condition is more frequently seen in younger patients and should be considered when patients present with leucocytosis and constitutional symptoms. In this report, we describe our diagnostic work-up for one such case using blood, lymph node, and bone marrow aspirate samples, highlighting the variability of antigen expression seen in different sample types and methodologies. This case shows the importance of having a high index of suspicion and assessing CD30 and anaplastic lymphoma kinase expression in all suspected T-cell neoplasms even though this rare condition is not necessarily expected

    Selective conversion of 5-hydroxymethylfurfural to cyclopentanone derivatives over Cu-Al2O3 and Co-Al2O3 catalysts in water

    Get PDF
    The production of cyclopentanone derivatives from 5-hydroxymethylfurfural (HMF) using non-noble metal based catalysts is reported for the first time. Five different mixed oxides containing Ni, Cu, Co, Zn and Mg phases on an Al-rich amorphous support were prepared and characterised (XRD, ICP, SEM, TEM, H2-TPR, NH3/CO2-TPD and N2 sorption). The synthesised materials resulted in well-dispersed high metal loadings in a mesoporous network, exhibiting acid/base properties. The catalytic performance was tested in a batch stirred reactor under H2 pressure (20–50 bar) in the range T = 140–180 °C. The Cu–Al2O3 and the Co–Al2O3 catalysts showed a highly selective production of 3-hydroxymethylcyclopentanone (HCPN, 86%) and 3-hydroxymethylcyclopentanol (HCPL, 94%), respectively. A plausible reaction mechanism is proposed, clarifying the role of the reduced metal phases and the acid/basic sites on the main conversion pathways. Both Cu–Al2O3 and Co–Al2O3 catalysts showed a loss of activity after the first run, which can be reversed by a regeneration treatment. The results establish an efficient catalytic route for the production of the diol HCPL (reported for the first time) and the ketone HCPN from bio-derived HMF over 3d transition metals based catalysts in an environmental friendly medium such as water

    Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial

    Get PDF
    Treatment with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) or escalated(e)-BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisolone) remains the international standard of care for advanced-stage classical Hodgkin lymphoma (HL). We performed a retrospective, multicentre analysis of 221 non-trial (“real-world”) patients, aged 16–59 years, diagnosed with advanced-stage HL in the Anglia Cancer Network between 2004 and 2014, treated with ABVD or eBEACOPP, and compared outcomes with 1088 patients in the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma (RATHL) trial, aged 18–59 years, with median follow-up of 87.0 and 69.5 months, respectively. Real-world ABVD patients (n=177) had highly similar 5-year progression-free survival (PFS) and overall survival (OS) compared with RATHL (PFS 79.2% vs 81.4%; OS 92.9% vs 95.2%), despite interim positron-emission tomography-computed tomography (PET/CT)-guided dose-escalation being predominantly restricted to trial patients. Real-world eBEACOPP patients (n=44) had superior PFS (95.5%) compared with real-world ABVD (HR 0.20, p=0.027) and RATHL (HR 0.21, p=0.015), and superior OS for higher-risk (international prognostic score ≥3 [IPS 3+]) patients compared with real-world IPS 3+ ABVD (100% vs 84.5%, p=0.045), but not IPS 3+ RATHL patients. Our data support a PFS, but not OS, advantage for patients with advanced-stage HL treated with eBEACOPP compared with ABVD and suggest higher-risk patients may benefit disproportionately from more intensive therapy. However, increased access to effective salvage therapies might minimise any OS benefit from reduced relapse rates after frontline therapy
    • …
    corecore